Can an older RSV drug protect healthy preterm babies from doctor visits?

When a healthy preterm baby catches RSV, it can quickly turn into a stressful trip to the doctor. A fresh look at older research suggests a preventive shot called palivizumab could be a strong shield. The analysis pooled data from three studies involving over 2,400 healthy infants born at 35 weeks or earlier. It found that for babies born between 29 and 35 weeks, palivizumab reduced these medically attended RSV infections by about 70% compared to a placebo shot. The researchers also noted its performance looked broadly similar to a newer drug, nirsevimab. But here's the catch: the researchers themselves flag that there's limited data on how well palivizumab prevents these specific outpatient infections. We're only seeing a percentage reduction, not the actual number of babies it helped. The report doesn't include any information on side effects or safety, which is a crucial piece of the puzzle for parents and doctors. This isn't a new clinical trial, but a re-analysis of existing studies, which means we're working with what was collected years ago. The finding is a useful data point, but it comes with significant unknowns that need to be filled in.